Table 1.
Baseline characteristics of vaccinated study participants (full analysis set).
| Group | 1.5/25 μg (N = 22) | 5.9/100 μg (N = 26) | Control (N = 24) |
|---|---|---|---|
| Age (mean ± SD), years | 24.6 ± 5.81 | 26.9 ± 8.44 | 28.3 ± 8.23 |
| Male, n (%) | 20 (91) | 23 (88) | 21 (88) |
| Weight (mean ± SD), kg | 59.6 ± 9.02 | 63.7 ± 9.29 | 60.4 ± 10.97 |
| Height (mean ± SD), cm | 169.7 ± 6.15 | 169.2 ± 6.73 | 167.2 ± 7.3 |
| Race, n (%) | |||
| Black | 21 (95) | 26 (100) | 24 (100) |
| White | 1 (5) | 0 | 0 |
| BMI (mean ± SD), kg/m2 | 20.7 ± 3.12 | 22.3 ± 3.34 | 21.6 ± 3.12 |
N, number of exposed participants in each group; n (%), number (percentage) of participants in each category; BMI, body mass index; 1.5/25 μg, 5.9/100 μg, participants who received the 1790GAHB vaccine with an O antigen/protein content of 1.5/25 and 5.9/100 μg, respectively, at days 1and 29; Control, participants who received meningococcal vaccine against serogroups A, C, W, and Y at day 1 and tetanus, diphtheria, and acellular pertussis vaccine at day 29.